193 related articles for article (PubMed ID: 34170389)
21. Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study.
Rizzari C; Lanvers-Kaminsky C; Valsecchi MG; Ballerini A; Matteo C; Gerss J; Wuerthwein G; Silvestri D; Colombini A; Conter V; Biondi A; Schrappe M; Moericke A; Zimmermann M; von Stackelberg A; Linderkamp C; Frühwald MC; Legien S; Attarbaschi A; Reismüller B; Kasper D; Smisek P; Stary J; Vinti L; Barisone E; Parasole R; Micalizzi C; Zucchetti M; Boos J
Haematologica; 2019 Sep; 104(9):1812-1821. PubMed ID: 30705097
[TBL] [Abstract][Full Text] [Related]
22. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia.
Hak LJ; Relling MV; Cheng C; Pei D; Wang B; Sandlund JT; Rubnitz J; Pui CH
Leukemia; 2004 Jun; 18(6):1072-7. PubMed ID: 15057247
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols.
Vieira Pinheiro JP; Ahlke E; Nowak-Göttl U; Hempel G; Müller HJ; Lümkemann K; Schrappe M; Rath B; Fleischhack G; Mann G; Boos J
Br J Haematol; 1999 Feb; 104(2):313-20. PubMed ID: 10050714
[TBL] [Abstract][Full Text] [Related]
24. Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia.
Kloos RQH; Pieters R; Jumelet FMV; de Groot-Kruseman HA; van den Bos C; van der Sluis IM
J Clin Oncol; 2020 Mar; 38(7):715-724. PubMed ID: 31922920
[TBL] [Abstract][Full Text] [Related]
25. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia.
Rizzari C; Citterio M; Zucchetti M; Conter V; Chiesa R; Colombini A; Malguzzi S; Silvestri D; D'Incalci M
Haematologica; 2006 Jan; 91(1):24-31. PubMed ID: 16434367
[TBL] [Abstract][Full Text] [Related]
26. How much asparaginase is needed for optimal outcome in childhood acute lymphoblastic leukaemia? A systematic review.
Brigitha LJ; Pieters R; van der Sluis IM
Eur J Cancer; 2021 Nov; 157():238-249. PubMed ID: 34536947
[TBL] [Abstract][Full Text] [Related]
27. Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia.
Wenner KA; Vieira Pinheiro JP; Escherich G; Wessalowski R; Jorch N; Wolff J; Stehn M; Kohlschütter A; Boos J; Janka-Schaub GE
Klin Padiatr; 2005; 217(6):321-6. PubMed ID: 16307417
[TBL] [Abstract][Full Text] [Related]
28. Pegaspargase: A Review in Acute Lymphoblastic Leukaemia.
Heo YA; Syed YY; Keam SJ
Drugs; 2019 May; 79(7):767-777. PubMed ID: 31030380
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.
Vrooman LM; Blonquist TM; Stevenson KE; Supko JG; Hunt SK; Cronholm SM; Koch V; Kay-Green S; Athale UH; Clavell LA; Cole PD; Harris MH; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Place AE; Schorin MA; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
J Clin Oncol; 2021 Nov; 39(31):3496-3505. PubMed ID: 34228505
[TBL] [Abstract][Full Text] [Related]
30. Depletion of d- and l-asparagine in cerebrospinal fluid in acute lymphoblastic leukemia during PEGasparaginase therapy.
Brigitha LJ; Pieters R; Struys EA; Bakkali A; van der Sluis IM
Pediatr Blood Cancer; 2022 Nov; 69(11):e29865. PubMed ID: 35880973
[TBL] [Abstract][Full Text] [Related]
31. L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase.
Gentili D; Conter V; Rizzari C; Tschuemperlin B; Zucchetti M; Orlandoni D; D'Incalci M; Masera G
Ann Oncol; 1996 Sep; 7(7):725-30. PubMed ID: 8905031
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future.
Avramis VI; Panosyan EH
Clin Pharmacokinet; 2005; 44(4):367-93. PubMed ID: 15828851
[TBL] [Abstract][Full Text] [Related]
33. PEGylated
Verma A; Chen K; Bender C; Gorney N; Leonard W; Barnette P
Pediatr Hematol Oncol; 2019 Aug; 36(5):277-286. PubMed ID: 31296092
[TBL] [Abstract][Full Text] [Related]
34. Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study.
Albertsen BK; Grell K; Abrahamsson J; Lund B; Vettenranta K; Jónsson ÓG; Frandsen TL; Wolthers BO; Heyman M; Schmiegelow K
J Clin Oncol; 2019 Jul; 37(19):1638-1646. PubMed ID: 30978155
[TBL] [Abstract][Full Text] [Related]
35. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).
Jarrar M; Gaynon PS; Periclou AP; Fu C; Harris RE; Stram D; Altman A; Bostrom B; Breneman J; Steele D; Trigg M; Zipf T; Avramis VI
Pediatr Blood Cancer; 2006 Aug; 47(2):141-6. PubMed ID: 16425271
[TBL] [Abstract][Full Text] [Related]
36. Clinical pharmacology of asparaginases in the United States: asparaginase population pharmacokinetic and pharmacodynamic (PK-PD) models (NONMEM) in adult and pediatric ALL patients.
Avramis VI; Spence SA
J Pediatr Hematol Oncol; 2007 Apr; 29(4):239-47. PubMed ID: 17414566
[TBL] [Abstract][Full Text] [Related]
37. Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries.
Albertsen BK; Schrøder H; Jakobsen P; Müller HJ; Carlsen NT; Schmiegelow K
Br J Clin Pharmacol; 2001 Oct; 52(4):433-7. PubMed ID: 11678787
[TBL] [Abstract][Full Text] [Related]
38. Higher plasma asparaginase activity after intramuscular than intravenous Erwinia asparaginase.
Panetta JC; Liu Y; Swanson HD; Karol SE; Pui CH; Inaba H; Jeha S; Relling MV
Pediatr Blood Cancer; 2020 Jul; 67(7):e28244. PubMed ID: 32323890
[TBL] [Abstract][Full Text] [Related]
39. Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia.
Vieira Pinheiro JP; Müller HJ; Schwabe D; Gunkel M; Casimiro da Palma J; Henze G; von Schütz V; Winkelhorst M; Würthwein G; Boos J
Br J Haematol; 2001 Apr; 113(1):115-9. PubMed ID: 11328290
[TBL] [Abstract][Full Text] [Related]
40. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.
Tong WH; Pieters R; Kaspers GJ; te Loo DM; Bierings MB; van den Bos C; Kollen WJ; Hop WC; Lanvers-Kaminsky C; Relling MV; Tissing WJ; van der Sluis IM
Blood; 2014 Mar; 123(13):2026-33. PubMed ID: 24449211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
